Psychomotor retardation in depression: Biological underpinnings, measurement, and treatment

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 35, Issue 2, 2011, Pages 395-409

  Buyukdura, Jeylan S ^a   McClintock, Shawn M ^a,b   Croarkin, Paul E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Major depressive disorder; Neuropsychological measures; Psychomotor retardation; Rating scales

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARGIPRESSIN; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HOMOVANILLIC ACID; HYDROCORTISONE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MINAPRINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

BASAL GANGLION; BRADYKINESIA; COGNITIVE DEFECT; CORE MEASURE; DEPRESSION; DISEASE SEVERITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; ELECTROCONVULSIVE THERAPY; EVOKED RESPONSE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MELANCHOLIA; MOTOR AGITATION AND RETARDATION SCALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PREDICTIVE VALUE; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOMOTOR RETARDATION; PSYCHOSIS; REVIEW; SALPETRIERE RETARDATION RATING SCALE; SHORT VERSION RETARDATION RATING SCALE FOR ELDERLY PATIENTS; SPEECH DISORDER; TRANSCRANIAL MAGNETIC STIMULATION;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR DISORDERS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 79952900156     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.10.019     Document Type: Review

References (156)

1. Aman M.G., Turbott S.H. Prediction of clinical response in children taking methylphenidate. J Autism Dev Disord 1991, 21(2):211-228.
2. Amsterdam J.D. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 1998, 12(3 Suppl B):S99-S111.
3. Antoni F.A. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993, 14(2):76-122.
4. Austin M.P., Mitchell P., Hadzi-Pavlovic D., Hickie I., Parker G., Chan J., et al. Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. Psychiatry Res 2000, 97(2-3):207-215.
5. Avery D., Silverman J. Psychomotor retardation and agitation in depression. Relationship to age, sex, and response to treatment. J Affect Disord 1984, 7(1):67-76.
6. Baeken C., De Raedt R., Santermans L., Zeeuws D., Vanderhasselt M.A., Meers M., et al. HF-rTMS treatment decreases psychomotor retardation in medication-resistant melancholic depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34(4):684-687.
7. Bajbouj M., Lisanby S.H., Lang U.E., Danker-Hopfe H., Heuser I., Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry 2006, 59(5):395-400.
8. Bange F., Bathien N. Visual cognitive dysfunction in depression: an event-related potential study. Electroencephalogr Clin Neurophysiol 1998, 108(5):472-481.
9. Benazzi F. Psychomotor changes in melancholic and atypical depression: unipolar and bipolar-II subtypes. Psychiatry Res 2002, 112(3):211-220.
10. Bench C.J., Friston K.J., Brown R.G., Frackowiak R.S., Dolan R.J. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med 1993, 23(3):579-590.
11. Bezzi G., Pinelli P., Tosca P. Motor reactivity, pain threshold and effects of sleep deprivation in unipolar depressives. Psychiatr Clin (Basel) 1981, 14(3):150-160.
12. Blackburn I.M. Mental and psychomotor speed in depression and mania. Br J Psychiatry 1975, 126:329-335.
13. Blewett A.E. Abnormal subjective time experience in depression. Br J Psychiatry 1992, 161:195-200.
14. Bonin-Guillaume S., Jouve E., Sautel L., Fakra E., Blin O. RRS-4: short version of the retardation rating scale to screen for depression in elderly inpatients. Am J Geriatr Psychiatry 2008, 16(4):331-335.
15. Brebion G., Smith M.J., Allilaire J.F. Psychometric characteristics of ideational retardation in depressives. Br J Clin Psychol 1995, 34(Pt 3):371-381.
16. Brody A.L., Barsom M.W., Bota R.G., Saxena S. Prefrontal-subcortical and limbic circuit mediation of major depressive disorder. Semin Clin Neuropsychiatry 2001, 6(2):102-112.
17. Brown W.A. Treatment response in melancholia. Acta Psychiatr Scand Suppl 2007, 433:125-129.
18. *D report. J Affect Disord 2008, 108(1-2):113-120.
19. Buchan H., Johnstone E., McPherson K., Palmer R.L., Crow T.J., Brandon S. Who benefits from electroconvulsive therapy? Combined results of the Leicester and Northwick Park trials. Br J Psychiatry 1992, 160:355-359.
20. Burns R.A., Lock T., Edwards D.R., Katona C.L., Harrison D.A., Robertson M.M., et al. Predictors of response to amine-specific antidepressants. J Affect Disord 1995, 35(3):97-106.
21. Caligiuri M.P., Gentili V., Eberson S., Kelsoe J., Rapaport M., Gillin J.C. A quantitative neuromotor predictor of antidepressant non-response in patients with major depression. J Affect Disord 2003, 77(2):135-141.
22. Calugi S., Cassano G.B., Litta A., Rucci P., Benvenuti A., Miniati M., et al. Does psychomotor retardation define a clinically relevant phenotype of unipolar depression?. J Affect Disord 2011, 129(1-3):296-300.
23. Canales J.J., Graybiel A.M. A measure of striatal function predicts motor stereotypy. Nat Neurosci 2000, 3(4):377-383.
24. Carlson G.A., Kashani J.H. Phenomenology of major depression from childhood through adulthood: analysis of three studies. Am J Psychiatry 1988, 145(10):1222-1225.
25. Carney M.W., Roth M., Garside R.F. The diagnosis of depressive syndromes and the prediction of E.C.T. response. Br J Psychiatry 1965, 111:659-674.
26. Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009, 21(4):371-380.
27. Danish University Antidepressant Group Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology (Berl) 1986, 90(1):131-138.
28. Danish University Antidepressant Group Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990, 18(4):289-299.
29. Danish University Antidepressant Group Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993, 28(2):105-116.
30. Dantchev N., Widlocher D.J. The measurement of retardation in depression. J Clin Psychiatry 1998, 59(Suppl 14):19-25.
31. de Winter R.F., van Hemert A.M., DeRijk R.H., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., Wiegant V.M., et al. Anxious-retarded depression: relation with plasma vasopressin and cortisol. Neuropsychopharmacology 2003, 28(1):140-147.
32. Del Zompo M., Bernardi F., Burrai C., Bocchetta A. A double-blind study of minaprine versus amitriptyline in major depression. Neuropsychobiology 1990, 24(2):79-83.
33. Demet M.M., Ozmen B., Deveci A., Boyvada S., Adiguzel H., Aydemir O. Depression and anxiety in hyperthyroidism. Arch Med Res 2002, 33(6):552-556.
34. Diagnostic and statistical manual of mental disorders. Fourth ed., text revision. Washington, DC: Author: American Psychiatric Association, 2000.
35. Fantino B., Moore N. The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in major depressive disorder. BMC Psychiatry 2009, 9:26.
36. Fink M., Rush A.J., Knapp R., Rasmussen K., Mueller M., Rummans T.A., et al. DSM melancholic features are unreliable predictors of ECT response: a CORE publication. J ECT 2007, 23(3):139-146.
37. Fitzgerald P.B., Brown T.L., Marston N.A., Daskalakis Z.J., de Castella A., Bradshaw J.L., et al. Motor cortical excitability and clinical response to rTMS in depression. J Affect Disord 2004, 82(1):71-76.
38. Flament M.F., Lane R.M., Zhu R., Ying Z. Predictors of an acute antidepressant response to fluoxetine and sertraline. Int Clin Psychopharmacol 1999, 14(5):259-275.
39. Foster F.G., Kupfer D.J. Psychomotor activity as a correlate of depression and sleep in acutely disturbed psychiatric inpatients. Am J Psychiatry 1975, 132(9):928-931.
40. Gill D., Lambourn J. Indications for electric convulsion therapy and its use by senior psychiatrists. Br Med J 1979, 1(6172):1169-1171.
41. Gorlyn M., Keilp J.G., Grunebaum M.F., Taylor B.P., Oquendo M.A., Bruder G.E., et al. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm 2008, 115(8):1213-1219.
42. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227(4688):770-773.
43. Greden J.F. Psychomotor monitoring: a promise being fulfilled?. J Psychiatr Res 1993, 27(3):285-287.
44. Greden J.F., Carroll B.J. Psychomotor function in affective disorders: an overview of new monitoring techniques. Am J Psychiatry 1981, 138(11):1441-1448.
45. Greden J.F., Albala A.A., Smokler I.A., Gardner R., Carroll B.J. Speech pause time: a marker of psychomotor retardation among endogenous depressives. Biol Psychiatry 1981, 16(9):851-859.
46. Guiard B.P., El Mansari M., Blier P. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009, 10(11). 1069-s84.
47. Gupta R.K. Major depression: an illness with objective physical signs. World J Biol Psychiatry 2009, 1-6.
48. Hardy P., Jouvent R., Widlocher D. Speech pause time and the retardation rating scale for depression (ERD). Towards a reciprocal validation. J Affect Disord 1984, 6(1):123-127.
49. Hegerl U., Gallinat J., Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord 2001, 62(1-2):93-100.
50. Heiligenstein J.H., Tollefson G.D., Faries D.E. Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord 1994, 30(3):163-173.
51. Herrera-Guzman I., Gudayol-Ferre E., Lira-Mandujano J., Herrera-Abarca J., Herrera-Guzman D., Montoya-Perez K., et al. Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry Res 2008, 160(1):72-82.
52. Herrero M.T., Barcia C., Navarro J.M. Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 2002, 18(8):386-404.
53. Hickie I., Parsonage B., Parker G. Prediction of response to electroconvulsive therapy. Preliminary validation of a sign-based typology of depression. Br J Psychiatry 1990, 157:65-71.
54. Hickie I., Scott E., Mitchell P., Wilhelm K., Austin M.P., Bennett B. Subcortical hyperintensities on magnetic resonance imaging: clinical correlates and prognostic significance in patients with severe depression. Biol Psychiatry 1995, 37(3):151-160.
55. Hickie I., Mason C., Parker G. Comparative validity of two measures of psychomotor function in patients with severe depression. J Affect Disord 1996, 37(2-3):143-149.
56. Hickie I., Mason C., Parker G., Brodaty H. Prediction of ECT response: validation of a refined sign-based (CORE) system for defining melancholia. Br J Psychiatry 1996, 169(1):68-74.
57. Hickie I., Ward P., Scott E., Haindl W., Walker B., Dixon J., et al. Neo-striatal rCBF correlates of psychomotor slowing in patients with major depression. Psychiatry Res 1999, 92(2-3):75-81.
58. Higuchi H., Sato K., Yoshida K., Takahashi H., Kamata M., Otani K., et al. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients. Psychiatry Clin Neurosci 2008, 62(3):301-306.
59. Higuchi H., Sato K., Yoshida K., Takahashi H., Kamata M., Otani K., et al. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders. Psychiatry Clin Neurosci 2008, 62(2):197-202.
60. Hobson R.F. Prognostic factors in electric convulsive therapy. J Neurol Neurosurg Psychiatry 1953, 16(4):275-281.
61. Hoeppner J., Padberg F., Domes G., Zinke A., Herpertz S.C., Grossheinrich N., et al. Influence of repetitive transcranial magnetic stimulation on psychomotor symptoms in major depression. Eur Arch Psychiatry Clin Neurosci 2010, 260(3):197-202.
62. Hoffmann G.M., Gonze J.C., Mendlewicz J. Speech pause time as a method for the evaluation of psychomotor retardation in depressive illness. Br J Psychiatry 1985, 146:535-538.
63. Hoppner J., Schulz M., Irmisch G., Mau R., Schlafke D., Richter J. Antidepressant efficacy of two different rTMS procedures. High frequency over left versus low frequency over right prefrontal cortex compared with sham stimulation. Eur Arch Psychiatry Clin Neurosci 2003, 253(2):103-109.
64. Hordern A., Holt N.F., Burt C.G., Gordon W.F. Amitriptyline in depressive states: phenomenology and prognostic considerations. Br J Psychiatry 1963, 109:815-825.
65. Hordern A., Burt C.G., Gordon W.F., Holt N.F. Amitriptyline in depressive states: six-month treatment results. Br J Psychiatry 1964, 110:641-647.
66. Iverson G.L. Objective assessment of psychomotor retardation in primary care patients with depression. J Behav Med 2004, 27(1):31-37.
67. Joffe R.T., Uhde T.W., Post R.M., Minichiello M.D. Motor activity in depressed patients treated with carbamazepine. Biol Psychiatry 1987, 22(8):941-946.
68. Jones I.H., Pansa M. Some nonverbal aspects of depression and schizophrenia occurring during the interview. J Nerv Ment Dis 1979, 167(7):402-409.
69. Joyce P.R., Mulder R.T., Luty S.E., McKenzie J.M., Sullivan P.F., Abbott R.M., et al. Melancholia: definitions, risk factors, personality, neuroendocrine markers and differential antidepressant response. Aust N Z J Psychiatry 2002, 36(3):376-383.
70. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol Psychiatry 1992, 32(1):1-17.
71. Kemp A.H., Gordon E., Rush A.J., Williams L.M. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008, 13(12):1066-1086. quiz 87-8.
72. Klein H.E., Bender W., Mayr H., Niederschweiberer A., Schmauss M. The DST and its relationship to psychiatric diagnosis, symptoms and treatment outcome. Br J Psychiatry 1984, 145:591-599.
73. Knott V.J., Lapierre Y.D. Electrophysiological and behavioral correlates of psychomotor responsivity in depression. Biol Psychiatry 1987, 22(3):313-324.
74. Kornstein S.G., Harvey A.T., Rush A.J., Wisniewski S.R., Trivedi M.H., Svikis D.S., et al. Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. Psychol Med 2005, 35(5):683-692.
75. Laakmann G., Blaschke D., Engel R., Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatry Suppl 1988, 3:64-68.
76. Lemke M.R., Puhl P., Koethe N., Winkler T. Psychomotor retardation and anhedonia in depression. Acta Psychiatr Scand 1999, 99(4):252-256.
77. Litvan I., Dickson D.W., Buttner-Ennever J.A., Delacourte A., Hutton M., Dubois B., et al. Research goals in progressive supranuclear palsy. First International Brainstorming Conference on PSP. Mov Disord 2000, 15(3):446-458.
78. Loo C.K., Sachdev P., Mitchell P.B., Gandevia S.C., Malhi G.S., Todd G., et al. A study using transcranial magnetic stimulation to investigate motor mechanisms in psychomotor retardation in depression. Int J Neuropsychopharmacol 2008, 11(7):935-946.
79. Lorr M., McNair D.M., Klett C.J., Lasky J.J. Inpatient Multidimensionul Psychiuiric Scale. Consulting Psychologists Press 1966, 549-558.
80. Mallinckrodt C.H., Watkin J.G., Liu C., Wohlreich M.M., Raskin J. Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005, 5:1.
81. Mallinckrodt C.H., Prakash A., Houston J.P., Swindle R., Detke M.J., Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007, 56(2-3):73-85.
82. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry 2001, 158(2):314-316.
83. Mayberg H.S., Starkstein S.E., Peyser C.E., Brandt J., Dannals R.F., Folstein S.E. Paralimbic frontal lobe hypometabolism in depression associated with Huntington's disease. Neurology 1992, 42(9):1791-1797.
84. Mayberg H.S., Lewis P.J., Regenold W., Wagner H.N. Paralimbic hypoperfusion in unipolar depression. J Nucl Med 1994, 35(6):929-934.
85. *D report. J Clin Psychiatry 2008, 69(12):1847-1855.
86. Mendels J. Electroconvulsive therapy and depression. 3. A method for prognosis. Br J Psychiatry 1965, 111:687-690.
87. Mendels J. Electroconvulsive therapy and depression. II. Significance of endogenous and reactive syndromes. Br J Psychiatry 1965, 111:682-686.
88. Mendels J. Electroconvulsive therapy and depression. I. The prognostic significance of clinical factors. Br J Psychiatry 1965, 111:675-681.
89. Minassian A., Henry B.L., Geyer M.A., Paulus M.P., Young J.W., Perry W. The quantitative assessment of motor activity in mania and schizophrenia. J Affect Disord 2010, 120(1-3):200-206.
90. Misdraji E.L., Gass C.S. The trail making test and its neurobehavioral components. J Clin Exp Neuropsychol 2009, 1-6.
91. Mitchell P.B. The new antidepressants - are they worth the cost?. Aust Prescriber 1995, 18:82-84.
92. Mitchell P.B. Managing depression in a community setting. Med J Aust 1997, 167(7):383-388.
93. Mitchell P.B., Malhi G.S. Bipolar depression: phenomenological overview and clinical characteristics. Bipolar Disord 2004, 6(6):530-539.
94. Mitchell P., Hadzi-Pavlovic D., Parker G., Hickie I., Wilhelm K., Brodaty H., et al. Depressive psychomotor disturbance, cortisol, and dexamethasone. Biol Psychiatry 1996, 40(10):941-950.
95. Moffoot A.P., O'Carroll R.E., Bennie J., Carroll S., Dick H., Ebmeier K.P., et al. Diurnal variation of mood and neuropsychological function in major depression with melancholia. J Affect Disord 1994, 32(4):257-269.
96. Morgan M., Phillips J.G., Bradshaw J.L., Mattingley J.B., Iansek R., Bradshaw J.A. Age-related motor slowness: simply strategic?. J Gerontol 1994, 49(3):M133-M139.
97. Mulder R.T., Joyce P.R., Frampton C.M., Luty S.E., Sullivan P.F. Six months of treatment for depression: outcome and predictors of the course of illness. Am J Psychiatry 2006, 163(1):95-100.
98. Naismith S., Hickie I., Ward P.B., Turner K., Scott E., Little C., et al. Caudate nucleus volumes and genetic determinants of homocysteine metabolism in the prediction of psychomotor speed in older persons with depression. Am J Psychiatry 2002, 159(12):2096-2098.
99. Narita H., Odawara T., Iseki E., Kosaka K., Hirayasu Y. Psychomotor retardation correlates with frontal hypoperfusion and the Modified Stroop Test in patients under 60-years-old with major depression. Psychiatry Clin Neurosci 2004, 58(4):389-395.
100. Neu P., Kiesslinger U., Schlattmann P., Reischies F.M. Time-related cognitive deficiency in four different types of depression. Psychiatry Res 2001, 103(2-3):237-247.
101. Niculescu A.B., Akiskal H.S. Proposed endophenotypes of dysthymia: evolutionary, clinical and pharmacogenomic considerations. Mol Psychiatry 2001, 6(4):363-366.
102. Parker G. Melancholia. Am J Psychiatry 2005, 162(6):1066.
103. Parker G., Hadzi-Pavlovic D. Melancholia: a disorder of movement and mood: a phenomenological and neurobiological review 1996, Cambridge University Press, Cambridge; New York, NY, USA.
104. Parker G., Fink M., Shorter E., Taylor M.A., Akiskal H., Berrios G., et al. Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder. Am J Psychiatry 2010, 167(7):745-747.
105. Petrides G., Fink M., Husain M.M., Knapp R.G., Rush A.J., Mueller M., et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001, 17(4):244-253.
106. Pier M.P., Hulstijn W., Sabbe B.G. No psychomotor slowing in fine motor tasks in dysthymia. J Affect Disord 2004, 83(2-3):109-120.
107. Pope B., Blass T., Siegman A.W., Raher J. Anxiety and depression in speech. J Consult Clin Psychol 1970, 35(1):128-133.
108. Ranelli C.J., Miller R.E. Behavioral predictors of amitriptyline response in depression. Am J Psychiatry 1981, 138(1):30-34.
109. Raoux N., Benoit O., Dantchev N., Denise P., Franc B., Allilaire J.F., et al. Circadian pattern of motor activity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course. Psychiatry Res 1994, 52(1):85-98.
110. Rasmussen K.G. Clinical applications of recent research on electroconvulsive therapy. Bull Menninger Clin 2003, 67(1):18-31.
111. Rasmussen-Torvik L.J., McAlpine D.D. Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils. Depress Anxiety 2007, 24(5):350-357.
112. Roose S.P., Glassman A.H., Attia E., Woodring S. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994, 151(12):1735-1739.
113. Ruohonen J., Karhu J. Navigated transcranial magnetic stimulation. Neurophysiol Clin 2010, 40(1):7-17.
114. Rush A.J., Weissenburger J.E. Melancholic symptom features and DSM-IV. Am J Psychiatry 1994, 151(4):489-498.
115. Sabbe B., van Hoof J., Hulstijn W., Zitman F. Depressive retardation and treatment with fluoxetine: assessment of the motor component. J Affect Disord 1997, 43(1):53-61.
116. Sabbe B., Hulstijn W., van Hoof J., Tuynman-Qua H.G., Zitman F. Retardation in depression: assessment by means of simple motor tasks. J Affect Disord 1999, 55(1):39-44.
117. Sabbe B., Hulstijn W., Maes M., Pier M., Scharpe S., Zitman F. Psychomotor slowing, neuroendocrine responses, and behavioral changes after oral administration of meta-chlorophenylpiperazine in normal volunteers. Psychiatry Res 2001, 105(3):151-163.
118. Sahakian B.J., Owen A.M. Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 1992, 85(7):399-402.
119. Samson J.A., Mirin S.M., Griffin M., Borrelli D., Schildkraut J.J. Urinary MHPG and clinical symptoms in patients with unipolar depression. Psychiatry Res 1994, 51(2):157-165.
120. Saxton J.A., Ratcliff G., Dodge H., Pandav R., Baddeley A., Ganguli M. Speed and capacity of language processing test: normative data from an older American community-dwelling sample. Appl Neuropsychol 2001, 8(4):193-203.
121. Schmid-Priscoveanu A., Allum J.H. Infrared and video oculography - alternatives to electrooculography?. HNO 1999, 47(5):472-478.
122. Schonfeldt-Lecuona C., Cardenas-Morales L., Freudenmann R.W., Kammer T., Herwig U. Transcranial magnetic stimulation in depression - lessons from the multicentre trials. Restor Neurol Neurosci 2010, 28(4):569-576.
123. Schrijvers D., de Bruijn E.R., Maas Y., De Grave C., Sabbe B.G., Hulstijn W. Action monitoring in major depressive disorder with psychomotor retardation. Cortex 2008, 44(5):569-579.
124. Schrijvers D., Hulstijn W., Sabbe B.G. Psychomotor symptoms in depression: a diagnostic, pathophysiological and therapeutic tool. J Affect Disord 2008, 109(1-2):1-20.
125. Schrijvers D., Maas Y.J., Pier M.P., Madani Y., Hulstijn W., Sabbe B.G. Psychomotor changes in major depressive disorder during sertraline treatment. Neuropsychobiology 2009, 59(1):34-42.
126. Schwartz G.E., Fair P.L., Salt P., Mandel M.R., Klerman G.L. Facial expression and imagery in depression: an electromyographic study. Psychosom Med 1976, 38(5):337-347.
127. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1997, 27(6):1247-1256.
128. Simon G.E., Von Korff M. Medical co-morbidity and validity of DSM-IV depression criteria. Psychol Med 2006, 36(1):27-36.
129. Smith J., Carr V., Morris H., Gilliland J. The dexamethasone suppression test in relation to symptomatology: preliminary findings controlling for serum dexamethasone concentrations. Psychiatry Res 1988, 25(2):123-133.
130. Smith M.J., Brebion G., Banquet J.P., Cohen L. Retardation of mentation in depressives: Posner's covert orientation of visual attention test. J Affect Disord 1995, 35(3):107-115.
131. Snaith R.P. Hamilton rating scale for depression. Br J Psychiatry 1977, 131:431-432.
132. Sobel R.M., Lotkowski S., Mandel S. Update on depression in neurologic illness: stroke, epilepsy, and multiple sclerosis. Curr Psychiatry Rep 2005, 7(5):396-403.
133. Sobin C., Sackeim H.A. Psychomotor symptoms of depression. Am J Psychiatry 1997, 154(1):4-17.
134. Sobin C., Mayer L., Endicott J. The motor agitation and retardation scale: a scale for the assessment of motor abnormalities in depressed patients. J Neuropsychiatry Clin Neurosci 1998, 10(1):85-92.
135. Starkstein S.E., Merello M., Jorge R., Brockman S., Bruce D., Petracca G., et al. A validation study of depressive syndromes in Parkinson's disease. Mov Disord 2008, 23(4):538-546.
136. Steele J.D., Glabus M.F., Shajahan P.M., Ebmeier K.P. Increased cortical inhibition in depression: a prolonged silent period with transcranial magnetic stimulation (TMS). Psychol Med 2000, 30(3):565-570.
137. Steffens D.C., Krishnan K.R. Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions. Biol Psychiatry 1998, 43(10):705-712.
138. Strian F., Albert W., Klicpera C. Course of depressive mood and psychomotor activation in endogenous depression. Arch Psychiatr Nervenkr 1979, 227(3):193-206.
139. Szabadi E., Bradshaw C.M., Besson J.A. Elongation of pause-time in speech: a simple, objective measure of motor retardation in depression. Br J Psychiatry 1976, 129:592-597.
140. Taylor B.P., Bruder G.E., Stewart J.W., McGrath P.J., Halperin J., Ehrlichman H., et al. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry 2006, 163(1):73-78.
141. Thase M.E., Trivedi M.H., Rush A.J. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995, 12(3):185-219.
142. The Northwick Park ECT trial Predictors of response to real and simulated ECT. Clinical Research Centre, Division of Psychiatry. Br J Psychiatry 1984, 144:227-237.
143. *D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
144. van Hoof J.J., Hulstijn W., van Mier H., Pagen M. Figure drawing and psychomotor retardation: preliminary report. J Affect Disord 1993, 29(4):263-266.
145. van Londen L., Goekoop J.G., van Kempen G.M., Frankhuijzen-Sierevogel A.C., Wiegant V.M., van der Velde E.A., et al. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997, 17(4):284-292.
146. van Londen L., Kerkhof G.A., van den Berg F., Goekoop J.G., Zwinderman K.H., Frankhuijzen-Sierevogel A.C., et al. Plasma arginine vasopressin and motor activity in major depression. Biol Psychiatry 1998, 43(3):196-204.
147. Vidailhet M., Bonnet A.M., Marconi R., Gouider-Khouja N., Agid Y. Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?. Neurology 1994, 44(9):1613-1616.
148. Videbech P., Ravnkilde B., Pedersen T.H., Hartvig H., Egander A., Clemmensen K., et al. The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr Scand 2002, 106(1):35-44.
149. Weller E.B., Weller R.A. Treatment options in the management of adolescent depression. J Affect Disord 2000, 61(Suppl 1):23-28.
150. White K., White J. Tranylcypromine: patterns and predictors of response. J Clin Psychiatry 1986, 47(7):380-382.
151. Whitwell J. Historical notes on psychiatry 1936, Lewis, London.
152. Widlocher D.J. Psychomotor retardation: clinical, theoretical, and psychometric aspects. Psychiatr Clin North Am 1983, 6(1):27-40.
153. Winograd-Gurvich C., Fitzgerald P.B., Georgiou-Karistianis N., Bradshaw J.L., White O.B. Negative symptoms: a review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull 2006, 70(4-6):312-321.
154. Yoshimura R., Nakamura J., Shinkai K., Ueda N. Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28(4):611-616.
155. Zarate C.A., Kando J.C., Tohen M., Weiss M.K., Cole J.O. Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?. J Clin Psychiatry 1996, 57(2):67-71.
156. Zilboorg G. A history of medical psychology 1944, Norton, New York.